Myocardial Infarction Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – Estimates DelveInsight | Amgen, Idorsia, CSL Behring, Kancera, Bayer, Recardio, Mesoblast

Myocardial Infarction Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) -  Estimates DelveInsight | Amgen, Idorsia, CSL Behring, Kancera, Bayer, Recardio, Mesoblast
Delveinsight Business Research LLP
The Myocardial Infarction Market size in the 7MM was USD 21,477 million in 2021, and it is projected to increase during the forecast period. As per DelveInsight, the Myocardial Infarction Market is anticipated to evolve immensely in the coming years owing to the expected launch of pipeline therapies and greater integration of early patient screening, medication in secondary care, and other clinical settings.

DelveInsight’s “Myocardial Infarction Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Myocardial Infarction market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Myocardial Infarction drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Myocardial Infarction treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Myocardial Infarction: An Overview

Myocardial Infarction (MI) is defined pathologically as myocardial cell death due to prolonged ischemia. Diminished cellular glycogen, relaxed myofibrils, and sarcolemmal disruption are the first ultrastructural changes seen as early as 10–15 min after the onset of ischemia.

Symptoms associated with myocardial infarction include chest pain, which may appear as a sensation of tightness or pressure initially. Pain often radiates to the left arm but may also radiate to the lower jaw, neck, right arm, back, and upper abdomen. Chest pain may accompany sweating, nausea or vomiting, and fainting. MI is categorized into three categories: Type I, II, and III. Myocardial Infarction caused by atherothrombotic coronary artery disease (CAD) and usually precipitated by atherosclerotic plaque disruption is designated as a Type I Myocardial Infarction, whereas the pathophysiological mechanism leading to ischemic myocardial injury in the context of a mismatch between oxygen supply and demand has been classified as Type II MI. In Type III, patients can manifest a typical presentation of myocardial ischemia/infarction, including presumed new ischemic ECG changes or ventricular fibrillation and die before obtaining blood for cardiac biomarker determination.

The use of biomarkers has likely improved the ascertainment of Myocardial Infarction over time, which would have the dual effects of potentially masking actual reductions in disease incidence because of primary prevention efforts and leading to false improvements in Myocardial Infarction-related case fatality attributable to the inclusion of smaller infarctions that previously would have been clinically unrecognized.

Myocardial Infarction Market Key Facts

  • The Myocardial Infarction market in 7MM will increase at a CAGR of 1.61% due to increasing awareness of the disease and the launch of the emerging therapy.

  • Among EU4 countries, Germany accounts for the maximum market size in 2021, while Spain occupies the bottom of the ladder in 2021.

  • The total Myocardial Infarction diagnosed prevalent cases in the 7MM were approximately 15 million in 2021 and are projected to increase during the forecasted period.

  • The total diagnosed prevalent cases of Myocardial Infarction in the United States were around 8 million in 2021.

  • The United States contributed to the largest prevalent population of Myocardial Infarction, acquiring ~52% of the 7MM in 2021. Whereas EU4, the UK, and Japan accounted for around 36% and 11% of the total population share, respectively, in 2021

  • Among the EU4 countries, Germany accounted for the largest number of diagnosed Myocardial Infarction cases, followed by France, whereas Spain accounted for the lowest number of cases in 2021.


Myocardial Infarction Market 

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Myocardial Infarction pipeline therapies. It also thoroughly assesses the Myocardial Infarction market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Myocardial Infarction drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Myocardial Infarction Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Myocardial Infarction epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Myocardial Infarction epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Myocardial Infarction Epidemiology, Segmented as –

  • Myocardial Infarction Diagnosed Prevalent Cases

  • Gender-specific Prevalence Cases of Myocardial Infarction

  • Type-specific Cases of Myocardial Infarction

Myocardial Infarction Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Myocardial Infarction market or expected to be launched during the study period. The analysis covers the Myocardial Infarction market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Myocardial Infarction drugs based on their sale and market share.

The report also covers the Myocardial Infarction pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Myocardial Infarction companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Myocardial Infarction Market Will Evolve and Grow by 2032 @

Myocardial Infarction Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Myocardial Infarction. Currency, GENERIUM Pharmaceuticals is leading the therapeutics market with its Myocardial Infarction drug candidates in the most advanced stage of clinical development.

Myocardial Infarction Companies Actively Working in the Therapeutics Market Include

AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Amgen, Novartis, Idorsia Pharmaceuticals, Faraday Pharmaceuticals,  CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, Mesoblast, and many others.

Emerging and Marketed Myocardial Infarction Therapies Covered in the Report Include:

  • FARXIGA/FORXIGA (dapagliflozin): AstraZeneca

  • JARDIANCE (empagliflozin): Boehringer Ingelheim and Eli Lilly and Company

  • Olpasiran: Amgen

  • INSPRA (eplerenone): Pfizer

  • PLAVIX (clopidogrel bisulfate): Sanofi-Aventis/Bristol-Myers Squibb

  • BRILINTA (ticagrelor): AstraZeneca

  • PRALUENT (alirocumab): Regeneron/Sanofi

And Many Others

The Report Covers an In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Myocardial Infarction Competitive Intelligence Analysis

4. Myocardial Infarction Market Overview at a Glance

5. Myocardial Infarction Disease Background and Overview

6. Myocardial Infarction Patient Journey

7. Myocardial Infarction Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Myocardial Infarction Treatment Algorithm, Current Treatment, and Medical Practices

9. Myocardial Infarction Unmet Needs

10. Key Endpoints of Myocardial Infarction Treatment

11. Myocardial Infarction Marketed Therapies

12. Myocardial Infarction Emerging Drugs and Latest Therapeutic Advances

13. Myocardial Infarction Seven Major Market Analysis

14. Attribute Analysis

15. Myocardial Infarction Market Outlook (In US, EU5, and Japan)

16. Myocardial Infarction Companies Active in the Market

17. Myocardial Infarction Access and Reimbursement Overview

18. KOL Views on the Myocardial Infarction Market

19. Myocardial Infarction Market Drivers

20. Myocardial Infarction Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Empower your business decisions with our comprehensive medical devices market research reports. Navigate industry dynamics and seize growth opportunities with data-driven insights, at: Medical Devices Market Research Reports

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States